With 2023 in the rear-view mirror, we at EpicentRx look ahead not only to 2024 but also to 2025 when we expect top-line data from five key EpicentRx clinical trials to read out.
For lead FDA Fast Tracked small molecule, RRx-001 (nibrozetone), these trials are the Phase 3 called REPLATINUM in small cell lung cancer (SCLC), the Phase 2b called KEVLARx for the prevention/amelioration of severe oral mucositis (SOM), and a Phase 1/2 in endometriosis at the University of Edinburgh, Scotland.
For lead TGF-β carrying oncolytic adenovirus, AdAPT-001, one trial called HAI MAINTENANCE will infuse AdAPT-001 through the hepatic artery to treat patients with liver-predominant colorectal cancer. In another called BETA PRIME, AdAPT-001 plus a checkpoint inhibitor will target sarcomas.
So, the itinerary has been set and we’re on a tight schedule to reach our ultimate destination, regulatory approval, hence it’s pedal to the metal time.
To learn more about our activities in Q4, check out our blog, press releases, and several new peer-reviewed publications linked below. Don’t forget to follow us on X and LinkedIn, too!
As always, thank you for taking the time to read and may the road rise up to meet you in 2024 and beyond,
The EpicentRx Team
Recent Press
- Age of posterity: Anti-inflammaging – a very modern dichotomy. PharmaTimes. December 2023.
- EpicentRx to Present Nibrozetone (RRx-001) Data on Parkinson’s Disease and ALS/MND at Neuroscience 2023. PR Newswire. November 2023.
- Partnering with EpicentRx. Translational Research Institute Australia. October 2023.
- “You are only as good as the company you keep” also applies to therapeutics like AdAPT-001 – EpicentRx. OncoDaily. October 2023.
Recent Publications
- BETA prime: a first-in-man phase 1 study of AdAPT-001, an armed oncolytic adenovirus for solid tumors. Cancer Gene Therapy. December 2023.
- Tutorial on Data Management. Translational Bytes. December 2023.
- Commentary on oncolytic viruses: past, present, and future. Journal for ImmunoTherapy of Cancer. November 2023.
Relevant Blog Posts
- NO Más. December 2023.
- Bloggin’ About the Noggin. December 2023.
- Richard Gordon Brings the Heat at the 2023 SfN Neuroscience Conference in Washington D.C. November 2023.
- Thank You SITC 2023. November 2023.
- We ❤️ RRx-001 (nibrozetone). October 2023.
- The Partnership Between EpicentRx and Queensland, Australia: A QUT Above. October 2023.